Update on Vaccine Development for Renal Cell Cancer

Overview

Journal Open Access J Urol

Publisher Dove Medical Press

Specialty Urology

Date 2013 Nov 8

PMID 24198621

Citations 4

Authors

Nina Chi

Jodi K Maranchie

Leonard J Appleman

Walter J Storkus

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) remains a significant health concern that frequently presents as metastatic disease at the time of initial diagnosis. Current first-line therapeutics for the advanced-stage RCC include antiangiogenic drugs that have yielded high rates of objective clinical response; however, these tend to be transient in nature, with many patients becoming refractory to chronic treatment with these agents. Adjuvant immunotherapies remain viable candidates to sustain disease-free and overall patient survival. In particular, vaccines designed to optimize the activation, maintenance, and recruitment of specific immunity within or into the tumor site continue to evolve. Based on the integration of increasingly refined immunomonitoring systems in both translational models and clinical trials, allowing for the improved understanding of treatment mechanism(s) of action, further refined (combinational) vaccine protocols are currently being developed and evaluated. This review provides a brief history of RCC vaccine development, discusses the successes and limitations in such approaches, and provides a rationale for developing combinational vaccine approaches that may provide improved clinical benefits to patients with RCC.

Citing Articles

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium.

Russell K, Gorgulho C, Allen A, Vakaki M, Wang Y, Facciabene A Cancer J. 2019; 25(3):165-177.

PMID: 31135523 PMC: 10395074. DOI: 10.1097/PPO.0000000000000374.

New treatment modalities with vaccine therapy in renal cell carcinoma.

Sonmez M, Ozturk Sonmez L Urol Ann. 2019; 11(2):119-125.

PMID: 31040593 PMC: 6476201. DOI: 10.4103/UA.UA_166_17.

Specific immunotherapy in renal cancer: a systematic review.

Hirbod-Mobarakeh A, Gordan H, Zahiri Z, Mirshahvalad M, Hosseinverdi S, Rini B Ther Adv Urol. 2017; 9(2):45-58.

PMID: 28203287 PMC: 5298411. DOI: 10.1177/1756287216681246.

Control of the adaptive immune response by tumor vasculature.

Mauge L, Terme M, Tartour E, Helley D Front Oncol. 2014; 4:61.

PMID: 24734218 PMC: 3975114. DOI: 10.3389/fonc.2014.00061.

References

Nicholas Haining W, Davies J, Kanzler H, Drury L, Brenn T, Evans J . CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008; 14(17):5626-34. DOI: 10.1158/1078-0432.CCR-08-0526. View

Dengjel J, Nastke M, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F . Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 2006; 12(14 Pt 1):4163-70. DOI: 10.1158/1078-0432.CCR-05-2470. View

Carmichael M, Benavides L, Holmes J, Gates J, Mittendorf E, Ponniah S . Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2009; 116(2):292-301. DOI: 10.1002/cncr.24756. View

Kaufman H, Taback B, Sherman W, Kim D, Shingler W, Moroziewicz D . Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009; 7:2. PMC: 2631474. DOI: 10.1186/1479-5876-7-2. View

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg K, Evrin K, Maes H . Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999; 163(2):1037-44. View

Elkord E, Burt D, Drijfhout J, Hawkins R, Stern P . CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol Immunother. 2007; 57(6):833-47. PMC: 11029843. DOI: 10.1007/s00262-007-0419-8. View

Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G . Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999; 84(3):268-72. DOI: 10.1002/(sici)1097-0215(19990621)84:3<268::aid-ijc12>3.0.co;2-8. View

Myers L, Lee S, Rossi R, Lefrancois L, Kwon B, Mittler R . Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol. 2005; 18(2):325-33. DOI: 10.1093/intimm/dxh371. View

Muller M, Grunebach F, Nencioni A, Brossart P . Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol. 2003; 170(12):5892-6. DOI: 10.4049/jimmunol.170.12.5892. View

10.

Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee J . Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007; 13(16):4840-8. DOI: 10.1158/1078-0432.CCR-07-0409. View

11.

Sercan O, Stoycheva D, Hammerling G, Arnold B, Schuler T . IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation. J Immunol. 2010; 184(6):2855-62. DOI: 10.4049/jimmunol.0902708. View

12.

Touloukian C, Leitner W, Robbins P, Li Y, Kang X, Lapointe R . Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 2002; 62(18):5144-7. PMC: 2248802. View

13.

Van den Eynde B, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F . A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med. 1999; 190(12):1793-800. PMC: 2195717. DOI: 10.1084/jem.190.12.1793. View

14.

Trinchieri G, Pflanz S, Kastelein R . The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003; 19(5):641-4. DOI: 10.1016/s1074-7613(03)00296-6. View

15.

Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S . Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005; 117(2):256-64. DOI: 10.1002/ijc.21200. View

16.

Cho H, Hayashi T, Datta S, Takabayashi K, Van Uden J, Horner A . IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol. 2002; 168(10):4907-13. DOI: 10.4049/jimmunol.168.10.4907. View

17.

Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H . Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14(24):8270-8. DOI: 10.1158/1078-0432.CCR-08-0165. View

18.

Hsu F, Komarovskaya M . CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother. 2002; 25(6):455-68. DOI: 10.1097/00002371-200211000-00002. View

19.

Gao L, Bellantuono I, Elsasser A, Marley S, Gordon M, Goldman J . Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95(7):2198-203. View

20.

Tatsumi T, Herrem C, Olson W, Finke J, Bukowski R, Kinch M . Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003; 63(15):4481-9. View